Home' Australian Pharmacist : Australian Pharmacist June 2012 Contents Australian Pharmacist June 2012 I ©Pharmaceutical Society of Australia Ltd. 503
and clinicians with additional treatment
options to help prevent the impact of
devastating conditions like stroke in people
living with non-valvular AF, a n for the
treatmen t of DVT.'
1. Xarelto Product Information. Apr 2012.
2. Turpie AG. Oral, direct factor Xa inhibitors in development for
the prevention and treatment of thromboembolic diseases.
Arterioscler. Throm. Vasc. Biol. 2007;27,(6)1238--47.
3. Holbrook A, Schulman S, Witt MD et al. Antithrombotic therapy
and prevention of thrombosis: An American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines
(9thEdition). Chest. 2012; 141(2), (Suppl) e152S-e184S
4. ARTG Public Summary: XARELTO (rivaroxaban) 13 Apr 2012.
Ikaria Australia Pty Ltd has announced
that Lucassin (terlipressin for injection),
which has recently been approved by
the Therapeutic Goods Administration
(TGA) for the treatment of Hepatorenal
Syndrome Type 1 (HRS Type 1) as the rst
and only approved medical therapy for
HRS Type 11 is now available to physicians.
HRS Type 1 is the rapid onset of renal failure
in patients with advanced liver cirrhosis
in the absence of any other cause2 and
results in a high mortality rate that exceeds
80% within three months.3 Over 1,500
people die from cirrhosis and liver diseases
every year in Australia.4 It is estimated that
18% of people with cirrhosis and ascites
will develop HRS within one year of their
diagnosis and 39% will develop it within
ve years.5 It is known that improvement
in renal function also improves transplant
outcomes in this patient population.5
Lucassin has been shown to reverse HRS
in at least a third of patients, providing
improved transplant-free survival in those
that responded to treatment.6 Professor
Geo McCaughan, Director, A W Morrow
Gastroenterology and Liver Centre, Royal
Prince Alfred Hospital and The Centenary
Institute and Chair of the Australian Liver
Association said, 'We are delighted that we
now have an approved treatment available
that provides an improved survival time for
patients. Patients with advanced cirrhosis
have little option except a liver transplant.
Securing a viable liver for transplantation is
di cult and preservation of renal function
is a key to a successful transplant, so being
able to maintain a patient's renal function
for as long as possible is vital'.
1. Registered medicine on Australian Register of Therapeutic
First-Aid App to help mum treat household cuts and burns.
Aspen Pharmacare, in consultation with La Trobe University's World of Wounds, has
developed the FAMILY FIRST-AID App, a handy guide to managing those more common
The FIRST-AID App gives customers quick and easy access
to information on treating superficial burns, cuts, grazes
and sunburn. It also provides advice on how to treat burns
following medical and cosmetic laser.
The FAMILY FIRST-AID App, available free from the App Store,
is an excellent educational resource for both customers and
The FAMILY FIRST-AID App is supported by Aspen's wound care
gel, FLAMIGEL. Indicated for superficial burns, cuts and grazes,
and sunburn, FLAMIGEL self-regulates to maintain the wound's
optimal moisture balance. FLAMIGEL provides simple, fast and
easy to use wound care for cuts, burns and grazes. It also helps
prevent infection,¹ aids healing, cools and rehydrates and
For further information please contact:
Karyn Lloyd; Senior Brand Manager, Aspen Pharmacare.
Aspen Pharmacare Australia Pty Ltd (ABN 51 096 236 985).
34-36 Chandos St, St Leonards NSW 2065. Ph +61 8436 8300
1. Beam JW. J Athletic Training 2007: 42(3):422-424.
2. Flamigel pack information.
2. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V (2007).
Diagnosis, prevention and treatment of hepatorenal syndrome
in cirrhosis. Gut 56 (9): 1310-8.
3. Ginès A, Escorsell A, Ginès P, et al. (1993). "Incidence, predictive
factors, and prognosis of the hepatorenal syndrome in cirrhosis
with ascites". Gastroenterology 105 (1): 229--36.
4. ABS. Causes of Death, Australia, 2009. http://abs.gov.au/
5. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria
C, Ozdogan O et al. Effects of treatment of hepatorenal
syndrome before transplantation on posttransplantation
outcome. A case-control study. J Hepatol 2004; 40(1):140-6
6. LUCASSIN Product Information. Jan 2012.
Actemra (tocilizumab), the only approved
biologic arthritis treatment designed to
block the protein messenger interleukin-6
(IL-6)1, will soon be available on the
Pharmaceutical Bene ts Scheme (PBS) for
children living with severe active systemic
Juvenile Idiopathic Arthritis (sJIA), a rare2
and aggressive3,4 form of arthritis.
Actemra will be listed
on the PBS from the
1 May 2012 for the
treatment of sJIA in
patients under 18
years of age.1 This listing extends its current
availability on the PBS for the treatment of
severe, active Rheumatoid Arthritis (RA) in
"I welcome the Government's decision to
provide subsidised access to a biologic
treatment option for systemic Juvenile
Idiopathic Arthritis -- a debilitating
condition that signi cantly impacts a child's
quality of life," said Dr Navid Adib, Paediatric
Rheumatologist at the Royal Children's
Hospital in Brisbane.
"The extension of the PBS listing of Actemra
means Australian parents and carers of
children living with systemic Juvenile
Idiopathic Arthritis will have a ordable
access to a treatment that can provide
substantial improvements to both the joint
and systemic e ects of arthritis."
Targeting in ammation at its source,
Actemra is speci cally designed to block
the action of the body's protein messenger
IL-6 which contributes to chronic
in ammation.1,6 IL-6 levels are elevated in
children with sJIA compared to other types
of juvenile arthritis and play a central role
in driving the systemic and articular e ects
Links Archive Australian Pharmacist July 2012 Australian Pharmacist May 2012 Navigation Previous Page Next Page